Savara Inc. has recently released its 10-K report, disclosing its financial condition, results of operations, and recent events. The company, a clinical-stage biopharmaceutical firm headquartered in Langhorne, Pennsylvania, is focused on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, currently in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis.
In the 10-K report, Savara Inc. highlighted its financial condition and results of operations. The company reported operating losses of $118.8 million and $95.9 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of $608.1 million as of December 31, 2025. Savara Inc. also noted that it had raised net cash proceeds of approximately $738.1 million since its inception, primarily from underwritten offerings of common stock, private placements of common stock, and debt financings. The company stated that it had never been profitable and has incurred operating losses in each year since inception.
As of December 31, 2025, Savara Inc. had cash and cash equivalents of $33.2 million and short-term investments of $202.5 million. The report also highlighted that the company may need to continue raising additional capital to further fund the development of its product candidate and begin commercialization if approved. The amount and timing of future funding requirements will depend on factors such as the pace and results of clinical development efforts.
Recent events outlined in the report included the resubmission of the BLA for MOLBREEVI to the FDA, a public offering of common stock that resulted in net proceeds of approximately $140.2 million, a royalty purchase and sale agreement, and a debt financing agreement. Additionally, the report mentioned the dismissal of securities class action claims and stockholder derivative actions against the company.
Savara Inc. also discussed its critical accounting policies and estimates, particularly in the areas of accrued research and development expenses and acquired IPR&D. The company emphasized that its estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities, and that actual results may differ materially from these estimates.
Following these announcements, the company's shares moved -1.02%, and are now trading at a price of $5.82. If you want to know more, read the company's complete 10-K report here.
